Roche Investor Relations ASCO Planner 2018

Transcription

1 Roche Investor Relations ASCO Planner 2018 Friday, June 1 Session Title: Hematologic Malignancies Plasma Cell Dyscrasia Date: Fri, June 1 Time: 2:45 PM - 5:45 PM Speaker Name: Luciano J. Costa 3:57 PM 4:09 PM Abstract 8004 Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Session Title: Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer: Caution Indicated! Session Type: Clinical Science Symposium Date: Fri, June 1 Location: Hall D1 Time: 4:30 PM - 6:00 PM Speaker Name: Dong-Wan Kim, MD, PhD 4:42 PM - 4:54 PM Abstract 9009 Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (ansclc). Saturday, June 2 Session Title: Genitourinary (Nonprostate) Cancer Date: Sat, June 2 Speaker Name: Arjun Vasant Balar, MD F. Hoffmann-La Roche Ltd 4070 Basel Switzerland Investor Relations investor.relations@roche.com Tel Fax

2 Abstract 4523 Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (muc): Long-term efficacy from phase 2 study IMvigor210. Poster Board #349 Session Title: Pediatric Oncology Date: Sat, June 2 Speaker Name: Ami Vijay Desai, MD, MSCE Abstract Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors. Poster Board #209 Sunday, June 3 Session Title: Breast Cancer Metastatic Location: Hall D2 Speaker Name: Jose Baselga, MD, PhD, FASCO; Rebecca Alexandra Dent, MD 10:00 AM - 10:12 AM Abstract LBA1006 Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. 10:24 AM - 10:36 AM Abstract 1008 Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mtnbc). Session Title: Genitourinary (Nonprostate) Cancer Location: Arie Crown Theater Speaker Name: Bernard Escudier, MD; Thomas Powles, MD 8:24 AM - 8:36 AM Abstract 4511 Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mrcc). 2/5

3 10:00 AM - 10:12 AM Abstract 4506 A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS). Session Title: Gastrointestinal (Noncolorectal) Cancer Speaker Name: Stacey Stein, MD Abstract 4074 Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). Poster Board #263 Session Title: Lung Cancer Non-Small Cell Metastatic Speaker Name: D. Ross Camidge, MD, PhD; Martin Reck, MD, PhD Abstract 9043 Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. Poster Board #366 Abstract 9047 Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mnsclc). Poster Board #370 Session Title: Hematologic Malignancies Lymphoma and Chronic Lymphocytic Leukemia Time: 9:45 AM - 12:45 PM Speaker Name: Laurie Helen Sehn, MD, MPH; Peter Hillmen, M.B., Ch.B. 11:45 AM - 11:57 AM Abstract 7507 Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. 11:57 AM - 12:09 PM Abstract 7508 High, durable minimal residual disease negativity (MRD ) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study. 3/5

4 Session Title: Plenary Session Including the Science of Oncology Award and Lecture Session Type: Plenary Session Location: Hall B1 Time: 1:00 PM - 4:00 PM Chair and/or Co-Chairs: Bruce E. Johnson, MD, FASCO; Ann H. Partridge, MD, MPH, FASCO; Daniel F. Hayes, MD, FACP, FASCO, BA; Douglas R. Lowy, MD; Joseph A. Sparano, MD; Lisa A. Carey, MD; Gianni Bisogno, MD; Douglas S. Hawkins, MD; Arnaud Mejean, MD, PhD; Daniel J. George, MD; Gilberto Lopes, MD, MBA; Leena Gandhi, MD, PhD Monday, June 4 Session Title: Lung Cancer Non-Small Cell Metastatic Date: Mon, June 4 Location: Hall B1 Time: 3:00 PM - 6:00 PM Speaker Name: Robert M. Jotte, MD, PhD; Mark A. Socinski, MD 3:00 PM - 3:12 PM Abstract LBA9000 IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. 3:45 PM - 3:57 PM Abstract 9002 Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. Session Title: Targeted Therapy in Leukemia Session Type: Clinical Science Symposium Date: Mon, June 4 Time: 4:30 PM - 6:00 PM Speaker Name: Courtney Denton Dinardo, MD 5:06 PM - 5:24 PM Abstract 7010 Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML). 4/5

5 Tuesday, June 5 Session Title: Tumor Biology Date: Tue, June 5 Location: S406 Speaker Name: Fatema A. Legrand, PhD; Vamsidhar Velcheti, MD; Gracy Crane 8:00 AM - 8:12 AM Abstract Association of high tissue TMB and atezolizumab efficacy across multiple tumor types. 8:12 AM - 8:24 AM Abstract Prospective clinical evaluation of blood-based tumor mutational burden (btmb) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B- F1RST results. 10:00 AM 10:12 AM Abstract Application of a real world endpoint to identify and characterize genetic profiles of patients (pts) with poor prognosis in advanced non-small-cell lung cancer (ansclc). 5/5